Brief: BeyondSpring Announces First Patient Dosed In Phase 2 Study Of First-Line Extensive-Stage Small-Cell Lung Cancer
25/03/2024 13:20
March 25 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES FIRST PATIENT DOSED WITH
PEMBROLIZUMAB, PLINABULIN PLUS ETOPOSIDE/PLATINUM IN A PHASE 2
INVESTIGATOR-INITIATED STUDY OF FIRST-LINE
EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
Source text for Eikon: ID:nGNX3TMT6z
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value